bioAffinity Technologies (BIAF) Common Equity (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Common Equity for 6 consecutive years, with $3.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 154.37% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $3.7 million (up 154.37% YoY), while the FY2025 annual figure was $7.3 million, up 179.69% from the prior year.
• Common Equity fell to $3.7 million in Q1 2026 per BIAF's latest filing, from $7.3 million in the prior quarter.
• Across five years, Common Equity topped out at $12.6 million in Q3 2022 and bottomed at -$16.8 million in Q2 2022.
• Historically, Common Equity has averaged $3.1 million across 5 years, with a median of $4.9 million in 2023.
• On a YoY basis, Common Equity climbed as much as 185.23% in 2025 and fell as far as 162.22% in 2025.
• bioAffinity Technologies' Common Equity stood at $11.0 million in 2022, then sank by 56.03% to $4.9 million in 2023, then sank by 46.41% to $2.6 million in 2024, then jumped by 179.69% to $7.3 million in 2025, then plunged by 49.69% to $3.7 million in 2026.
• Business Quant data shows BIAF's Common Equity at $3.7 million in Q1 2026, $7.3 million in Q4 2025, and $8.9 million in Q3 2025.